background
middl
east
respiratori
syndrom
coronaviru
merscov
caus
respiratori
diseas
case
fatal
rate
given
potenti
caus
public
health
emerg
absenc
efficaci
drug
vaccin
mer
one
prioriti
diseas
warrant
urgent
research
develop
countermeasur
aim
assess
safeti
toler
antimerscov
modifi
vaccinia
viru
ankara
mva
base
vaccin
candid
express
merscov
spike
glycoprotein
mvamerss
healthi
adult
method
openlabel
phase
trial
done
univers
medic
center
hamburgeppendorf
hamburg
germani
particip
healthi
men
women
age
year
clinic
signific
health
problem
determin
medic
histori
physic
examin
bodymass
index
weight
kg
screen
neg
pregnanc
test
women
key
exclus
criterion
previou
mva
vaccin
prime
immunis
particip
receiv
dose
plaqueform
unit
pfu
lowdos
group
pfu
highdos
group
mvamerss
intramuscularli
second
ident
dose
administ
intramuscularli
booster
immunis
day
first
inject
control
group
immunogen
analys
blood
sampl
drawn
ident
studi
timepoint
six
healthi
adult
receiv
inject
primari
object
studi
safeti
toler
two
dosag
level
reactogen
administr
immunogen
assess
secondari
endpoint
elisa
neutralis
test
tcell
immun
evalu
enzymelink
immun
absorb
spot
assay
particip
vaccin
least
includ
safeti
analysi
immunogen
analys
particip
complet
month
followup
trial
regist
clinicaltrialsgov
eudract
find
dec
june
particip
lowdos
group
highdos
group
enrol
receiv
first
dose
vaccin
accord
group
alloc
particip
lowdos
group
highdos
group
receiv
second
dose
mvamerss
accord
group
alloc
interv
complet
followup
homolog
primeboost
immunis
mvamerss
reveal
benign
safeti
profil
transient
mildtomoder
reactogen
particip
sever
seriou
advers
event
vaccinerel
advers
event
report
ten
particip
lowdos
group
report
ten
particip
highdos
group
solicit
local
reaction
common
advers
event
pain
observ
seven
lowdos
group
vs
ten
highdos
group
particip
swell
ten
two
vs
eight
particip
indur
ten
one
vs
nine
particip
headach
observ
seven
particip
lowdos
group
vs
nine
highdos
group
fatigu
malais
ten
vs
seven
particip
common
solicit
system
advers
event
advers
event
resolv
swiftli
within
day
without
sequela
follow
booster
immunis
nine
particip
lowdos
group
particip
highdos
group
show
seroconvers
use
merscov
elisa
timepoint
studi
bind
antibodi
titr
correl
merscovspecif
neutralis
antibodi
spearman
correl
ci
merscov
spikespecif
tcell
respons
detect
ten
immunis
particip
lowdos
group
ten
immunis
particip
highdos
group
interpret
vaccin
mvamerss
favour
safeti
profil
without
seriou
sever
advers
event
homolog
primeboost
immunis
induc
humor
cellmedi
respons
merscov
doseeffect
relationship
demonstr
reactogen
vaccineinduc
immun
respons
data
present
support
clinic
test
mvamerss
larger
cohort
advanc
mer
vaccin
develop
wwwthelancetcominfect
publish
onlin
april
http
doi
middl
east
respiratori
syndrom
mer
viral
respiratori
ill
activ
surveil
place
list
prioriti
diseas
high
epidem
potenti
warrant
urgent
research
develop
countermeasur
diseas
lower
respiratori
tract
human
mer
progress
rapidli
unspecif
influenzalik
symptom
sever
pneumonia
multipl
organ
failur
death
caus
agent
mer
mer
coronaviru
merscov
first
identifi
saudi
arabia
dromedari
camel
serv
reservoir
host
major
primari
human
case
trace
back
close
frequent
contact
dromedari
addit
humantohuman
transmiss
amplifi
healthcar
set
ad
healthcar
worker
popul
high
risk
jan
case
report
death
countri
result
casefat
rate
larg
mer
outbreak
occur
saudi
arabia
case
death
south
korea
case
death
although
transmiss
predominantli
report
arabian
peninsula
high
risk
export
case
area
outsid
middl
east
result
travel
far
support
therapi
isol
patient
contact
trace
remain
main
pillar
mer
treatment
prevent
highlight
urgent
need
develop
countermeasur
vaccin
block
transmiss
combat
potenti
futur
diseas
outbreak
develop
mer
vaccin
candid
challeng
determin
protect
immun
remain
incomplet
understood
limit
number
mer
case
made
difficult
efficaci
trial
although
optim
anim
model
identif
protect
immun
correl
mer
still
scarc
current
mous
model
suggest
crucial
role
antibodi
cell
induct
protect
immun
human
one
studi
show
posit
correl
tcell
respons
neutralis
antibodi
sever
diseas
progress
posit
correl
strong
virusspecif
tcell
respons
reduc
mor
biditi
convers
anoth
studi
report
posit
associ
earli
tcell
respons
diseas
sever
acut
merscov
infect
role
antibodi
protect
shown
mice
receiv
convalesc
sera
survivor
anim
human
data
underlin
mer
vaccin
candid
preferenti
induc
humor
cellmedi
immun
respons
time
dose
vaccin
could
crucial
protect
studi
use
recombin
modifi
vaccinia
viru
ankara
rmva
vaccin
vector
platform
shown
safe
immuno
genic
human
mva
vaccin
candid
demon
strate
favour
safeti
profil
variou
popul
diseas
set
merscov
spike
glycoprotein
consist
subunit
mediat
viral
attach
host
cell
entri
membran
fusion
target
neutralis
antibodi
therefor
vaccin
develop
evid
studi
middl
east
respiratori
syndrom
mer
zoonot
viral
respiratori
ill
caus
mer
coronaviru
merscov
mer
activ
surveil
scrutini
far
licens
vaccin
avail
prevent
diseas
viral
spread
mvamerss
novel
vaccin
candid
base
recombin
modifi
vaccinia
viru
ankara
mva
vaccin
vector
platform
report
safe
immunogen
mice
dromedari
camel
search
clinicaltrialsgov
aug
keyword
mer
vaccin
five
studi
list
except
one
studi
evalu
immunoglobulin
treatment
mer
four
test
mer
vaccin
platform
three
vaccin
platform
test
phase
trial
mva
dna
vaccin
latter
progress
phase
trial
dna
vaccin
phase
trial
done
usa
phase
studi
recent
initi
seoul
south
korea
first
human
data
mer
vaccin
candid
publish
juli
present
safeti
immunogen
dna
vaccin
candid
aim
assess
safeti
immunogen
data
first
mva
viral
vector
vaccin
candid
mer
proceed
clinic
trial
studi
provid
comprehens
result
phase
trial
test
mva
vectorbas
vaccin
express
merscov
protein
studi
reveal
benign
safeti
profil
mvamerss
provid
first
insight
immunogen
vaccin
candid
particip
receiv
high
dose
plaqueform
unit
pfu
experienc
mildtomoder
advers
event
show
seroconvers
patient
show
tcell
respons
lowdos
group
pfu
show
similar
safeti
profil
seroconvers
particip
tcell
immun
particip
aftermath
ebola
viru
outbreak
west
africa
flag
need
time
develop
vaccin
highthreat
pathogen
includ
merscov
data
present
support
clinic
develop
candid
vaccin
mvamerss
add
critic
insight
field
vaccin
research
coronavirus
emerg
pathogen
mer
vaccin
candid
mvamerss
investig
studi
encod
full
merscov
spike
glycoprotein
preclin
studi
shown
mvamerss
induc
neutralis
antibodi
confer
protect
merscov
mice
express
dipeptidyl
peptidas
receptor
furthermor
reduct
viral
replic
merscov
challeng
mvamerss
vaccin
success
demonstr
dromedari
camel
preclin
data
support
advanc
vaccin
candid
mvamerss
test
safeti
immunogen
human
clinic
trial
aim
assess
safeti
toler
immunogen
data
novel
viralvector
mer
candid
vaccin
healthi
adult
openlabel
phase
studi
done
univers
medic
center
hamburgeppendorf
hamburg
germani
particip
recruit
public
advertis
includ
men
women
age
year
clinic
signific
health
problem
determin
medic
histori
physic
examin
bodymass
index
weight
kg
screen
neg
pregnanc
test
women
key
exclus
criterion
previou
mva
immunis
full
list
inclus
exclus
criteria
provid
protocol
appendix
pp
particip
provid
written
inform
consent
studi
design
review
approv
compet
nation
author
paulehrlichinstitut
langen
germani
ethic
committe
hamburg
medic
associ
studi
done
accord
declar
helsinki
fortaleza
brazil
intern
confer
harmonis
good
clinic
practic
local
safeti
monitor
board
provid
clinic
oversight
mvamerss
base
rmva
vector
encod
fulllength
merscov
spike
glycoprotein
base
sequenc
genbank
access
number
vaccin
manufactur
idt
biologika
dessau
germani
primari
chicken
embryo
fibroblast
prime
immunis
particip
receiv
dose
plaqueform
unit
pfu
lowdos
group
pfu
highdos
group
mvamerss
intramuscularli
deltoid
muscl
nondomin
arm
second
ident
dose
administ
intramuscularli
booster
immunis
day
first
inject
safeti
reason
particip
vaccin
stagger
manner
appendix
p
day
administr
prime
boost
dose
last
studi
particip
lowdos
group
review
safeti
data
local
safeti
board
stagger
mode
vaccin
appli
highdos
group
control
group
immunogen
analys
blood
sampl
drawn
ident
studi
timepoint
six
healthi
adult
receiv
inject
individu
underw
physic
examin
drug
pregnanc
test
receiv
electrocardiogram
even
immunis
clinic
trial
center
north
hamburg
germani
heart
rate
blood
pressur
bodi
temperatur
record
studi
personnel
h
h
h
h
h
h
vaccin
blood
drawn
chemic
haematolog
safeti
analys
particip
monitor
longitudin
day
studi
visit
day
vaccin
day
day
vaccin
day
day
vaccin
includ
two
overnight
stay
approxim
durat
h
day
prime
immunis
day
booster
immunis
clinic
laboratori
evalu
done
studi
visit
appendix
p
laboratori
analys
includ
measur
complet
blood
count
creatinin
creactiv
protein
crp
troponin
liver
function
marker
local
system
reactogen
well
medic
use
record
particip
day
vaccin
daili
notif
sheet
record
followup
visit
studi
personnel
advers
event
classifi
mild
interfer
activ
daili
live
moder
interfer
daili
live
activ
pose
substanti
perman
risk
particip
sever
consider
affect
daili
live
clinic
statu
advers
event
assess
categoris
basi
whether
solicit
expect
therefor
predefin
protocol
unsolicit
event
solicit
event
includ
local
pain
indur
red
haematoma
swell
inject
site
system
advers
event
fever
chill
fatigu
malais
myalgia
arthralgia
headach
gastrointestin
symptom
diarrhoea
loos
stool
abdomin
cramp
nausea
unsolicit
advers
event
event
defin
solicit
event
aros
day
well
day
day
booster
vaccin
occurr
seriou
advers
event
monitor
throughout
studi
seriou
advers
event
defin
event
result
death
lifethreaten
requir
inpati
hospit
admiss
caus
prolong
exist
hospit
stay
result
persist
disabl
requir
inter
vention
prevent
perman
impair
damag
advers
event
list
grade
studi
personnel
accord
common
terminolog
criteria
advers
event
version
medic
dictionari
regulatori
activ
appendix
pp
serum
analys
day
evalu
humor
immun
respons
see
onlin
appendix
elisa
coat
microtitr
plate
merscov
protein
previous
describ
absorb
measur
nm
cutoff
set
optic
densiti
optimis
commerci
merscov
elisa
assay
euroimmun
lubeck
germani
done
posthoc
addit
analysi
presenc
merscovneutralis
antibodi
sera
particip
investig
viru
neutralis
test
use
measur
neutralis
capac
sera
cell
infect
merscov
four
replic
reciproc
titr
consid
posit
previous
describ
neutralis
defin
absenc
cytopath
effect
addit
sera
test
neutralis
capac
plaqu
reduct
neutralis
test
use
plaqu
reduct
neutral
isat
test
prnt
titr
serum
sampl
reciproc
valu
highest
dilut
result
infect
reduct
prnt
titr
consid
posit
detail
three
method
describ
appendix
pp
peripher
blood
mononuclear
cell
pbmc
isol
cryopreserv
edta
blood
use
ficol
densiti
gradient
centrifug
tcell
respons
assess
link
enzymelink
immun
absorb
spot
elispot
immunospot
cellular
technolog
cleveland
oh
usa
plate
follow
thaw
rest
pbmc
stimul
h
triplic
five
overlap
peptid
pool
span
entir
merscov
amino
acid
sequenc
phytohemagglutinin
pool
cytomegaloviru
epsteinbarr
viru
influenza
peptid
pool
jpt
peptid
technolog
berlin
germani
serv
posit
control
serumfre
medium
cellular
technolog
supplement
dimethyl
sulphoxid
serv
neg
control
respons
defin
posit
two
criteria
met
first
spotform
cell
sfc
per
million
pbmc
second
number
sfc
per
million
pbmc
four
time
higher
baselin
day
valu
detail
see
appendix
p
antigenspecif
cell
analys
use
flowcytometri
follow
overnight
rest
pbmc
incub
h
overlap
peptid
pool
cell
analys
lsrfortessa
bd
bioscienc
franklin
lake
nj
usa
evalu
version
flowjo
ashland
usa
primari
endpoint
frequenc
sever
advers
event
measur
occurr
solicit
local
system
reactogen
sign
symptom
day
vaccin
occurr
unsolicit
advers
event
day
vaccin
chang
baselin
safeti
laboratori
measur
occurr
seriou
advers
event
throughout
studi
period
month
secondari
endpoint
immunogen
magnitud
merscov
spikespecif
antibodi
respons
measur
elisa
preplan
exploratori
analys
includ
evalu
tcell
immun
elispot
trial
design
exploratori
trial
power
statist
measur
specif
outcom
determin
dose
find
particip
vaccin
least
includ
safeti
analysi
immunogen
analys
particip
complet
month
followup
record
advers
event
depict
frequenc
particip
dose
group
experienc
least
one
advers
event
indic
symptom
group
case
particip
report
two
advers
event
differ
degre
symptom
group
sever
event
record
correl
bind
neutralis
antibodi
merscov
spearman
correl
elisa
optic
densiti
valu
reciproc
titr
neutralis
antibodi
analys
data
wilcoxon
signedrank
test
pair
sampl
mannwhitney
u
test
unpair
sampl
p
valu
less
consid
signific
p
valu
correct
multipl
comparison
statist
analys
use
graphpad
prism
version
trial
regist
clinicaltrialsgov
eudract
funder
investigatoriniti
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
dec
june
individu
screen
particip
enrol
figur
detail
particip
baselin
characterist
summaris
tabl
three
individu
one
lowdos
group
two
highdos
group
receiv
booster
immunis
exclud
immunogen
analysi
howev
data
includ
safeti
investig
two
particip
lowdos
group
discontinu
person
reason
within
first
day
studi
replac
replac
complet
followup
visit
third
person
highdos
group
drop
receiv
booster
immunis
unrel
urinari
tract
infect
day
person
replac
stage
trial
full
primeboost
vaccin
regimen
administ
particip
interv
day
particip
complet
schedul
followup
visit
month
one
particip
lowdos
group
move
day
followup
visit
day
chang
resid
timepoint
exclud
immuno
genic
analysi
protocol
violat
monitor
acut
reactogen
follow
immunis
seriou
advers
event
report
vaccinerel
advers
event
report
ten
particip
lowdos
group
report
ten
particip
highdos
group
major
solicit
mild
moder
sever
advers
event
advers
event
appear
earli
administr
vaccin
median
day
iqr
highdos
group
advers
event
prime
boost
immunis
lowdos
group
figur
advers
event
resolv
quickli
median
day
iqr
gener
requir
treatment
solicit
local
reaction
common
advers
event
pain
observ
seven
particip
lowdos
group
vs
ten
highdos
group
parti
cipant
swell
ten
two
vs
eight
particip
indur
ten
one
vs
nine
particip
headach
observ
seven
particip
lowdos
group
vs
nine
particip
highdos
group
fatigu
malais
ten
vs
seven
particip
common
solicit
system
advers
event
figur
detail
advers
event
list
appendix
pp
two
particip
highdos
group
elev
temperatur
fever
h
prime
immunis
temperatur
respect
appendix
pp
signific
transient
asymptomat
decreas
white
blood
cell
neutrophil
count
day
day
well
lymphocyt
thrombo
cyte
count
day
day
observ
highdos
group
figur
tabl
lowdos
group
also
similar
differ
lower
extent
crp
concentr
day
significantli
higher
highdos
group
lowdos
group
appendix
p
laboratori
paramet
vital
sign
show
signific
alter
vaccin
data
shown
seroconvers
detect
particip
nine
particip
lowdos
group
particip
highdos
group
timepoint
throughout
studi
tabl
antibodi
respons
predominantli
detect
second
vaccin
dose
either
low
high
dose
mvamerss
two
vaccin
particip
one
lowdos
group
one
highdos
group
show
posit
elisa
respons
day
singl
mvamerss
administr
day
boost
immunis
day
merscov
antibodi
detect
dose
group
tabl
major
vaccin
particip
show
posit
elisa
respons
day
tabl
control
group
particip
seroneg
except
one
particip
show
borderlin
optic
densiti
valu
day
exact
cutoff
valu
seroposit
figur
tabl
geometr
mean
optic
densiti
valu
antibodi
concentr
day
similar
cohort
tabl
antibodi
concentr
group
decreas
time
posit
elisa
respons
still
observ
particip
day
day
three
particip
lowdos
group
none
highdos
group
remain
posit
merscov
spikespecif
antibodi
observ
signific
dose
depend
immunogen
readout
lowdos
highdos
group
day
day
day
mannwhitney
u
test
data
shown
posthoc
addit
immuno
genic
investig
optimis
commerci
elisa
assay
euroimmun
show
similar
confirmatori
result
appendix
pp
timepoint
throughout
studi
sera
particip
vaccin
neutralis
merscov
use
viru
neutralis
test
figur
singl
inject
mvamerss
show
induct
neutralis
antibodi
viru
neutralis
test
reveal
detect
neutralis
capac
boost
mainli
particip
lowdos
group
peak
respons
day
seven
particip
react
posit
compar
two
particip
highdos
group
end
studi
day
two
one
dose
group
still
detect
neutralis
capac
viru
neutralis
test
sensit
prnt
assay
figur
antibodi
respons
mirror
similar
pattern
observ
use
inhous
elisa
figur
singl
vaccin
administr
induc
neutralis
antibodi
one
particip
lowdos
group
boost
immunis
nine
particip
lowdos
group
nine
particip
highdos
group
show
respons
boost
elicit
signific
increas
neutralis
antibodi
respons
day
compar
baselin
group
day
p
group
wilcoxon
signedrank
test
appendix
p
linear
correl
elisa
optic
densiti
valu
reciproc
titr
neutralis
antibodi
pnrt
observ
day
ci
figur
suggest
high
proport
function
antibodi
among
vaccineinduc
merscov
spikespecif
bind
antibodi
highest
number
posit
respons
inhous
merscov
elisa
prnt
assay
detect
day
vaccin
particip
seven
lowdos
group
nine
highdos
group
data
shown
antibodi
direct
vaccin
vector
also
assess
boost
vaccin
mvaspecif
neutralis
antibodi
detect
vaccin
recipi
eight
lowdos
group
highdos
group
correl
merscovspecif
bind
neutralis
antibodi
respons
observ
data
shown
merscov
spikespecif
tcell
respons
evalu
elispot
use
five
overlap
peptid
pool
figur
repres
elispot
well
shown
appendix
p
tcell
respons
merscov
spike
emerg
singl
vaccin
mvamerss
particip
enhanc
boost
immunis
overal
secret
detect
ten
particip
lowdos
group
ten
particip
highdos
group
one
timepoint
throughout
studi
tcell
respons
observ
peptid
pool
howev
respons
pool
frequent
detect
figur
group
show
increas
secret
compar
day
detect
lowdos
group
day
highdos
group
day
earliest
peak
respons
observ
day
appendix
p
highest
magnitud
respons
observ
two
particip
lowdos
group
upon
stimul
sfc
per
million
pbmc
respect
addit
posthoc
analysi
subgroup
six
particip
three
group
demonstr
merscov
spikespecif
secret
predominantli
cell
rather
cell
use
flowcytometri
appendix
p
take
account
number
assay
respond
time
dose
cohort
show
similar
pattern
earliest
assay
respond
identifi
day
figur
day
lowdos
group
six
particip
one
particip
remov
day
analysi
outlin
previous
still
show
posit
tcell
respons
highdos
group
one
particip
show
respons
evalu
breadth
tcell
respons
assess
number
pool
particip
respond
highdos
group
reveal
respons
one
pool
alreadi
day
reduc
breadth
time
com
parison
lowdos
group
show
increas
breadth
boost
immunis
figur
taken
togeth
data
show
immunis
mvamerss
induc
tcell
respons
decreas
studi
period
remain
detect
follow
homolog
prime
boost
immunis
mvamerss
singl
sever
seriou
advers
event
observ
particip
receiv
either
low
dose
high
dose
vaccin
particip
experienc
transient
selflimit
mildtomoder
advers
event
mostli
dosedepend
local
reaction
well
unspecif
system
advers
event
data
demonstr
favour
safeti
profil
dose
two
administr
safeti
signal
similar
observ
phase
trial
test
influenza
vaccin
particip
receiv
dose
ident
mva
backbon
similar
safeti
profil
observ
trial
use
mva
platform
insert
antigen
deriv
pathogen
comparison
mvamerss
vaccineinduc
safeti
profil
suggest
vectorspecif
rather
insertspecif
safeti
signal
merscovspecif
advers
event
outlin
brighton
collabor
observ
vaccin
mvamerss
elicit
humor
cellular
immun
respons
merscov
spike
mostli
detect
follow
boost
rather
prime
immunis
humor
immun
respons
measur
elisa
two
differ
viral
neutralis
assay
reveal
peak
antibodi
respons
day
maintain
day
declin
baselin
level
major
studi
particip
end
studi
month
vaccin
although
exact
contribut
merscovspecif
antibodi
immun
protect
mer
remain
elucid
preclin
data
support
role
protect
viru
challeng
anim
model
signific
reduct
excret
infecti
viru
viral
rna
transcript
mvamerssvaccin
dromedari
camel
observ
follow
merscov
challeng
associ
merscovspecif
neutralis
antibodi
albeit
optim
anim
model
mous
studi
support
investig
protect
mechan
mice
suscept
merscov
express
human
transgen
mice
adenoviralmedi
deliveri
merscov
infect
mous
cell
challeng
experi
support
impact
antibodi
immun
protect
passiv
immunotherapi
subsequ
challeng
experi
ment
evalu
passiv
immunotherapi
merscov
challeng
use
merscovspecif
mono
clonal
antibodi
sera
obtain
merscovposit
immun
dromedari
camel
show
protect
mice
express
human
although
safeti
toler
antimerscov
polyclon
antibodi
treat
ment
human
demonstr
protect
mer
human
yet
document
notabl
mous
experi
demonstr
gener
neutralis
antibodi
upon
mvamerss
vaccin
partial
mediat
neutralis
receptorbind
domain
rbd
indic
part
merscov
spike
glycoprotein
might
also
induc
neutralis
antibodi
context
notabl
outcom
mous
experi
protect
capac
nonrbd
neutralis
mous
antibodi
merscov
furthermor
demonstr
monoclon
antibodi
show
moder
neutralis
capac
vitro
highli
protect
challeng
vivo
suggest
strong
neutralis
activ
condit
protect
futur
analys
therefor
includ
merscov
also
antibodi
assay
function
antibodi
readout
beyond
neutralis
capac
current
understudi
systemsserolog
approach
includ
nonneutralis
function
antibodydepend
cellular
cytotox
antibodydepend
cellular
phagocytosi
might
provid
insight
mvamerssinduc
immun
dissect
addi
tional
mechan
antibodymedi
protect
howev
note
although
anim
studi
indic
crucial
role
antibodi
protect
mer
human
data
avail
merscovinfect
individu
far
reveal
clear
strong
correl
merscovspecif
antibodi
respons
merscov
viral
load
report
individu
merscov
infect
reveal
predominantli
tcell
respons
oppos
antibodi
respons
survivor
well
expos
dromedari
camel
worker
although
yet
determin
tcell
respons
crucial
merscov
clearanc
human
anim
model
provid
evid
cell
support
viral
clearanc
mice
studi
detect
vaccineinduc
tcell
respons
merscov
spike
present
even
second
immunis
respons
persist
day
third
studi
particip
seven
particip
suggest
vaccineinduc
tcell
respons
maintain
slightli
longer
humor
immun
respons
three
particip
observ
stronger
robust
tcell
respons
lowdos
group
highdos
group
although
find
signific
might
consid
futur
studi
focu
dose
find
includ
larger
number
particip
howev
exact
contribut
tcell
immun
vaccineinduc
natur
protect
diseas
viral
clearanc
remain
determin
need
investig
complement
analys
vaccineinduc
immun
merscov
spike
antigen
insert
vector
vaccin
also
investig
vector
immun
mva
backbon
mvaspecif
humor
respons
mva
vector
assess
posthoc
use
viru
neutralis
test
assay
wildtyp
mva
address
potenti
effect
merscov
spikespecif
antibodi
although
mvaspecif
neutralis
antibodi
induc
correl
merscovspecif
bind
neutralis
antibodi
respons
observ
current
strong
evid
induc
preexist
mvaspecif
immun
interfer
vaccineinduc
immun
respons
use
mva
vector
studi
trial
use
show
mvabas
vaccin
elicit
antibodi
respons
antigen
insert
follow
second
third
immunis
despit
induct
antivector
immun
prime
inject
exact
impact
preexist
immun
respons
mva
requir
investig
futur
studi
rapid
induct
vaccineinduc
immun
follow
singleshot
vaccin
scheme
consid
part
cularli
use
outbreak
scenario
howev
mvamerss
show
induct
strong
mvamerssspecif
immun
respons
follow
singl
prime
vaccin
might
reduc
direct
applic
acut
outbreak
scenario
context
limit
human
data
correl
protect
current
challeng
predict
whether
mvamerss
suitabl
rapidli
evolv
epidem
situat
remain
unclear
specif
paramet
relev
defenc
merscov
conceiv
homolog
mva
primeboost
vaccin
might
final
optimis
vaccin
schedul
mvamerss
differ
strategi
includ
heterolog
primeboost
regimen
evalu
futur
trial
sever
mer
vaccin
candid
current
test
phase
clinic
trial
coalit
epidem
prepared
innov
fund
five
differ
vaccin
platform
mvamerss
dna
advanc
first
mer
vaccin
trial
human
report
date
investig
dnabas
vaccin
homolog
primeboostboost
regim
use
similar
studi
author
observ
favour
safeti
profil
induct
humor
cellular
immun
respons
although
seroreact
cellular
respons
larg
maintain
studi
period
week
neutralis
antibodi
detect
vaccin
recipi
peak
week
second
boost
rapidli
declin
addit
clinic
trial
need
evalu
whether
heterolog
primeboost
vaccin
schedul
mvamerss
dna
prime
boost
mvamerss
induc
immun
respons
protect
merscov
infect
least
favour
modul
mer
diseas
cours
studi
warrant
improv
detail
understand
role
antibodi
titr
neutralis
nonneutralis
antibodi
cellular
immun
respons
natur
vaccineinduc
pro
tectiv
merscovspecif
immun
enhanc
acceler
strateg
vaccin
develop
mer
ultim
assess
vaccin
efficaci
challeng
outbreak
unpredict
number
mer
case
rel
low
although
data
present
make
valuabl
contribut
mer
vaccin
agenda
enterpris
studi
also
limit
restrict
number
studi
particip
phase
trial
limit
generalis
result
necessit
followup
studi
larger
cohort
studi
also
includ
addit
late
boost
induc
strong
increas
antibodi
respons
previou
trial
earli
studi
format
also
allow
data
gener
antibodi
depend
enhanc
context
merscov
infect
previous
discuss
sever
acut
respiratori
syndrom
sar
coronaviru
futur
studi
anim
model
possibl
includ
adopt
transfer
experi
sera
deriv
vaccin
individu
well
clinic
trial
need
address
crucial
aspect
conclus
phase
trial
investig
candid
vaccin
mvamerss
show
benign
safeti
profil
provid
first
evid
humor
cellular
immunogen
induc
candid
vaccin
human
data
gener
far
support
develop
mer
vaccin
candid
homolog
heterolog
vaccin
scheme
possibl
involv
viral
vector
vaccin
coalit
epidem
prepared
innov
includ
mvamerss
fund
portfolio
support
scalabl
manufactur
clinic
develop
evalu
safeti
immunogen
larger
cohort
endem
area
favour
profil
mvamerss
might
also
make
use
contribut
develop
futur
vaccin
strategi
coronaviru
pathogen
recent
emerg
sar
coronaviru
howev
crucial
knowledg
gap
remain
address
blh
list
inventor
middl
east
respiratori
syndrom
coronaviru
patent
applic
author
declar
compet
interest
individu
particip
data
share
includ
data
dictionari
individu
particip
data
collect
trial
share
deidentif
document
made
avail
includ
studi
protocol
inform
consent
form
data
avail
immedi
follow
public
end
dateth
data
share
anyon
wish
access
data
data
avail
purpos
analys
data
pleas
contact
correspond
author
